Responses
Clinical/translational cancer immunotherapy
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.